Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
12/2018 not set
Alcobra Pharmaceuticals
Alcobra Pharmaceuticals Overview
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.
In 2017, six months after Alcobras clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.
Alcobra Pharmaceuticals Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Feb 5, 2018
www.globes.co.il
Arcturus Therapeutics board fires CEO
#Management Changes
Nov 15, 2017
globenewswire.com
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
#Acquisition #Public Trading #Management Changes
Sep 28, 2017
www.globes.co.il
Alcobra to merge with US co Arcturus
#Acquisition #Investment
Nov 15, 2015
www.globes.co.il
Israeli co Alcobra raises $40m in Nasdaq offering
#Investment
Sep 15, 2015
www.globes.co.il
Alcobra awarded fast track designation for FragileX drug